{"count": 1, "results": [{"_id": "34079271", "pmid": 34079271, "pmcid": "PMC8164213", "title": "Epigenetic Therapies for Heart Failure: Current Insights and Future Potential", "journal": "Vasc Health Risk Manag", "authors": ["Napoli C", "Bontempo P", "Palmieri V", "Coscioni E", "Maiello C", "Donatelli F", "Benincasa G"], "date": "2021-05-24T00:00:00Z", "doi": "10.2147/VHRM.S287082", "meta_date_publication": "2021", "meta_volume": "17", "meta_issue": "", "meta_pages": "247-254", "score": 50269.668, "text_hl": "...The use of @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@ has been generally considered a contraindication in @<m>DISEASE_Heart_Failure_Systolic</m> @DISEASE_MESH:D054143 @@@HFrEF@@@ @SPECIES_9606 @@@patients@@@ owing the potential risk of @DISEASE_Acidosis_Lactic @DISEASE_MESH:D000140 @@@lactic acidosis@@@; however, recent evidence has reported that @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@ can provide beneficial effects in reducing the risk of incident HF and mortality in @DISEASE_Diabetes_Mellitus @DISEASE_MESH:D003920 @@@diabetic@@@ @SPECIES_9606 @@@patients@@@. ", "citations": {"NLM": "Napoli C, Bontempo P, Palmieri V, Coscioni E, Maiello C, Donatelli F, Benincasa G. Epigenetic Therapies for Heart Failure: Current Insights and Future Potential Vasc Health Risk Manag. 2021;17():247-254. PMID: 34079271", "BibTeX": "@article{34079271, title={Epigenetic Therapies for Heart Failure: Current Insights and Future Potential}, author={Napoli C and Bontempo P and Palmieri V and Coscioni E and Maiello C and Donatelli F and Benincasa G}, journal={Vasc Health Risk Manag}, volume={17}, pages={247-254}}"}}]}